Target Information

Aminolabs, established thirty years ago, has emerged as a leading global player in the high-quality sports nutrition and dietary supplements sector. In 2015, Waterland Private Equity acquired a majority stake in Aminolabs, marking the initiation of a significant structural growth phase for the company. Under Waterland's guidance, Aminolabs expanded through multiple acquisitions both domestically and internationally, solidifying its position as a top-tier contract manufacturer for powders, capsules, and tablets.

As a prominent supplier in the sports nutrition and dietary supplement market, Aminolabs has diversified its product offerings to include functional food bars, which led to the establishment of a separate entity, EMPWR, in 2020. This spin-off has proven successful, generating over 160 million euros in revenue in 2022. Roger Anné and Waterland Private Equity remain key shareholders in EMPWR, demonstrating their continued commitment to the sector.

Industry Overview

The dietary supplement industry in which Aminolabs operates has witnessed substantial growth over recent years. The market dynamics have evolved, with a shift in focus from solely athletes to a broader audience that includes health-conscious consumers. Increasing awareness regarding the importance of nutrition and healthy living has prompted more individuals, including non-athletes, to incorporate dietary supplements into their daily routines.

In Europe, specifically, the demand for sports nutrition and health supplements has surged. As lifestyles become more sedentary and dietary awareness grows, the market for healthy snacks and nutritional supplements is expected to flourish further. Aminolabs strategically positions itself to leverage this trend, aiming to cater to the evolving needs of consumers seeking healthier alternatives.

As societal concerns over health continue to rise, the dietary supplement sector is poised for continuous growth. Innovations in product offerings and a commitment to quality will be pivotal in capitalizing on this market trend. Aminolabs is well equipped to meet these demands, with a robust infrastructure and a focus on research and development.

Rationale Behind the Deal

The recent management buy-out of Aminolabs aims to realign the shareholder structure while empowering the management team to play a more significant role in the company's future. Roger Anné expressed gratitude for Waterland Private Equity’s past investments that enabled Aminolabs to achieve its stature in the industry. By acquiring an increased ownership stake and welcoming LRM as a minority investor, the company can maintain its strategic direction and focus on innovation and growth.

This restructuring allows Aminolabs to ensure continuity in its operations and ambition. The motivation behind the management buy-out is to foster a collaborative environment that encourages further investments in innovation and sustained growth in the years ahead.

Investor Information

Waterland Private Equity has been instrumental in Amalolabs' success since its initial investment in 2015. The firm's active involvement and strategic support have facilitated multiple acquisitions and operational enhancements, enabling Aminolabs to flourish in the competitive dietary supplement market. As a well-regarded investment firm, Waterland focuses on growth-oriented opportunities across various sectors.

The partnership with LRM signifies a commitment to ongoing investment in the company's development. As minority stakeholders, both Waterland and LRM will continue to provide the necessary resources and strategic guidance to foster innovation and growth at Aminolabs, ensuring its competitive edge in the market.

View of Dealert

The management buy-out of Aminolabs represents a strategic shift that could yield significant benefits for the company’s long-term growth. From an investment perspective, this move appears promising. By increasing the management team's stake, they are likely to align their interests closely with the company's performance, fostering a culture of accountability and innovation.

Moreover, the entrance of LRM as a minority investor adds valuable resources and expertise to Aminolabs. The fresh capital coupled with the management's commitment to innovation positions the company favorably to capitalize on the burgeoning demand in the dietary supplement market. With a consistent annual growth ambition of 20 to 25 percent, Aminolabs is well on its way to becoming a dominant player in Europe.

In conclusion, this restructuring, alongside Aminolabs' commitment to quality and innovation, suggests that the management buy-out could indeed be a sound investment. The alignment of management and investor interests, coupled with a robust growth strategy, makes Aminolabs an attractive prospect for long-term success in the competitive nutrition sector.

View Original Article